Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 427-432

  Moro Sibilot, Denis ^a   Smit, Egbert ^b   de Castro Carpeño, Javier ^c   Lesniewski Kmak, Krzysztof ^d   Aerts, Joachim G ^e,f   Villatoro, Rosa ^g   Kraaij, Kees ^h   Nacerddine, Karim ^h   Dyachkova, Yulia ⁱ   Smith, Karen T ^h   Girvan, Allicia ^h   Visseren Grul, Carla ^h   Schnabel, Philipp A ^j  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e AMPHIA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g HOSPITAL COSTA DEL SOL   (Spain)

^h ELI LILLY AND COMPANY   (United States)

ⁱ Eli Lilly GmbH   (Austria)

^j SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Carboplatin; Cisplatin; Metastases; Non small cell lung cancer; Observational study

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; PLATINUM;

ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GROUPS BY AGE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT DURATION; ADULT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; EUROPE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETREATMENT; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; RETREATMENT; TREATMENT OUTCOME;

EID: 84949213469     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.11.011     Document Type: Article

References (15)

1. Cancer Research UK. Mortality Statistics . http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/mortality/uk-lung-cancer-mortality-statistics#geog.
2. Crinò L., Weder W., van Meerbeeck J., Felip E. ESMO guidelines working group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21:v103-v115.
3. Arrieta O., Villarreal-Garza C., Zamora J., Blake-Cerda M., de la Mata M.D., Zavala D.G., et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat. Oncol. 2011, 6:166.
4. Reck M., Popat S., Reinmuth D., De Ruysscher D., Kerr K.M., Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25(Suppl. 3):iii27-iii39.
5. Robinet G., Thomas P., Breton J.L., Lena H., Gouva S., Dabouis G., et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de PneumoCancerologie (GFPC) Protocol 95-1*. Ann. Oncol. 2001, 12(1):59-67.
6. Barlesi F., Gervais R., Lena H., Hureaux J., Berard H., Paillontin D., et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann. Oncol. 2011, 22(11):2466-2470.
7. Besse B., Le Moulec S., Mazières J., Senellart H., Barlesi F., Chouaid C., et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase ii study. Clin. Cancer Res. 2015, 21(8):1896-1903.
8. Zimmermann S., Dziadziuszko R., Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat. Rev. 2014, 40(6):716-722.
9. Moro-Sibilot D., Smit E., de Castro Carpeño J., Lesniewski-Kmak K., Aerts J., Villatoro R., et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer 2015, 88(2):215-222. 10.1016/j.lungcan.2015.02.011.
10. Schnabel P.A., Smit E., Carpeño Jde C., Leśniewski-Kmak K., Aerts J., Kraaij K., et al. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). Lung Cancer 2012, 78(3):263-269.
11. AJJC Cancer Staging Manual 1997, Lippincott-Raven, Philadelphia, PA. 5th ed. I.D. Fleming, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, G.P. Murphy, B. O'sullivan (Eds.).
12. Sperduto P.W., Kased N., Roberge D., Xu Z., Shanley R., Luo X., et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 2012, 30(4):419-425.
13. Ali A., Goffin J.R., Arnold A., Ellis P.M. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr. Oncol. 2013, 20(4):300-306.
14. Samer A., Rekha C., Nagla K. Frontline systemic therapy with pemetrexed-platinum in nonsquamous non-small-cell lung cancer with asymptomatic brain metastases. Am. J. Ther. 2015, (in press).
15. Karachaliou N., Rosell R. Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors. Ann. Palliat. Med. 2013, 2(3):114-117.